Agilent Technologies Signs Co-Marketing Agreement with MRM Proteomics to Advance Quantitative Proteomics Solutions

Agilent Technologies Inc. (NYSE:A) today announced it has extended a co-marketing agreement with MRM Proteomics Inc., a leading provider of advanced protein quantitation, biomarker and proteomic services. The agreement expands on an existing collaboration established in 2012 and will allow both organizations to bolster their combined proteomics solutions, comprising reagent kits, hardware and software.

“MRM Proteomics is a pioneer in the development of mass-spec-based methods for protein quantification and a leading provider of technologies for the pharmaceutical and biotechnology industries,” said Steve Fischer, market director for Agilent’s Life Science Research Group. “This collaboration further reflects our commitment to building a comprehensive portfolio of quantitative proteomics solutions for those growing industries.”

Proteomics is the study of the structure and function of proteins and how they interact within a complex biological system. Agilent’s integrated proteomics workflow provides the industry’s highest analytical performance and features unprecedented plug-and-play flexibility. Interchangeable workflows simplify setups and let researchers quickly switch between different methodologies. Offering the industry’s highest sensitivity and highest throughput quantitation, the Agilent 6495 Triple Quadrupole MS/MS provides targeted MRM peptide quantitation at attomole detection levels.

The field of mass spectrometry continues to widen to meet the growing demands of fundamental proteomics research, biomarker discovery/validation and drug development. MRM Proteomics specializes in the provision of services and kits for the highly multiplexed absolute quantitation of proteins in complex biological samples, such as blood, cerebrospinal fluid and urine, through MRM-MS using isotopically labeled internal standards.

“MRM Proteomics is delighted to expand upon our complementary partnership with Agilent,” said Christoph Borchers, chief scientific officer at MRM Proteomics. “Agilent is an ideal partner because of its cutting-edge and high-sensitivity mass spectrometry technologies. The company shares our focus on delivering complete turnkey solutions for targeted quantitative proteomics.”

About MRM Proteomics

MRM Proteomics is a leader in providing services and consumable kits for advanced protein quantitation and proteomics to the pharmaceutical, biotechnology and diagnostics industries. The company’s key technology, targeted quantitative proteomics by MRM-MS, is highly suitable for biomarker discovery/validation, clinical studies, diagnostics and toxicology. Information about MRM Proteomics is available at www.mrmproteomics.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.